Zydus Cadila has received final USFDA approval to market levofloxacin injection, used to treat bacterial infections, in the American market. The drug injection is made available in strengths of 500 mg/20mL and 750mg/30 ml. The company will manufacture the product at its Moraiya plant in Gujarat. This is the first approval from its Moraiya plant after the USFDA audit in February 2017. It may be noted, the Gujarat group has more than 115 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Company Profile : Cadila Healthcare Ltd
Leave a Reply